Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.

New 6-triazolyl-substituted sulfocoumarins were described as potent inhibitors of the transmembrane human carbonic anhydrase isoforms, CAIX and CAXII. These membrane associated enzymes that maintain pH and CO2 homeostasis are involved in cancer progression, invasion, and resistance to therapy. Recently, it was shown that CAXII expression associates with the expression of P-glycoprotein in multidrug resistant cancer cells. CAXII regulates P-glycoprotein activity by maintaining high intracellular pHi. In this study, the activity of three new sulfocoumarins was evaluated in three sensitive and corresponding multidrug resistant cancer cell lines with increased P-glycoprotein expression (non-small cell lung carcinoma, colorectal carcinoma and glioblastoma). Compound 3 showed the highest potential for cancer cell growth inhibition in all tested cell lines. Flow cytometric analyses showed that compound 3 induced intracellular acidification, cell cycle arrest in G2/M phase and necrosis in non-small cell lung carcinoma cells. Compound 3 demonstrated irreversible, concentration- and time-dependent inhibition of P-glycoprotein activity in multidrug resistant non-small cell lung carcinoma cells. The suppression of P-glycoprotein activity was accompanied with increased P-glycoprotein expression suggesting a compensatory mechanism of multidrug resistant cancer cells. In addition, compound 3 was able to sensitize multidrug resistant non-small cell lung carcinoma cells to doxorubicin. Overall, results imply that compound 3 has multidrug resistance modulating effect through intracellular acidification and subsequent inhibition of P-glycoprotein activity.

The Effect of Lysozyme on Reducing Biofilms by Staphylococcus aureus, Pseudomonas aeruginosa, and Gardnerella vaginalis: An In Vitro Examination.

Two basic questions about lysozyme activities on the selected microorganisms were investigated, namely whether lysozyme inhibits biofilm production and which concentrations of the enzyme have the ability to change the natural biofilm producing capacity of different strains of Staphylococcus aureus (methicillin sensitive and resistant), Streptococcus pyogenes, Pseudomonas aeruginosa, and Gardnerella vaginalis. The effect of lysozyme on biofilm formation capacities of 16 strains of selected microorganisms was investigated, whereby four testing replicates have been performed in vitro using the Test Tube method, and the potential of lysozyme to change biofilm forming capacities depending on its concentration, species, and strains of microorganisms is demonstrated. A lysozyme concentration of 30 µg/ml indicated to have the highest inhibiting effect on all tested microorganisms. Furthermore, G. vaginalis was the most sensitive of them all, as its biofilm formation was inhibited in the presence of as low as 2.5 µg/ml of lysozyme. At enzyme concentrations of 7.5-50 µg/ml (with the exception of 30 µg/ml) the biofilm forming capacities of P. aeruginosa were enhanced. Depending on the strain of P. aeruginosa, the total biofilm quantity was either reduced or unaffected at lysozyme concentrations of 2.5, 5, 7.5, and 30 µg/ml. In contrast, lysozyme concentrations below 15 or 20 µg/ml did not affect or increase the volume of biofilm formation, while higher concentrations (15, 20, 25 µg/ml) reduced biofilm formation by 50% (3/6) and 30 µg/ml of biofilm reduced biofilm forming capacity of S. aureus by 100% (6/6). The results of this study are a strong foundation for further research on lysozyme as a modulator of the biofilm forming capacity of different species with the potential to aid in the development of new drugs for the treatment of oral and vaginal infections.